We read with interest the work by Haug et al. published in Gut. 1 Longitudinal data from 4,523 participants in the first round of a faecal immunochemical test for haemoglobin (FIT) based screening programme, of whom 3,427 also participated in the second round, were studied. In both first and second rounds, a threshold of 10 µg Hb/g faeces was used. The cohort was followed up for two years. The cumulative positivity and the number of participants diagnosed with neoplasia over the two rounds of screening were determined and compared with a hypothetical strategy involving single round screening with use of lower faecal haemoglobin concentration (f-Hb) thresholds and omission of the second round. It was suggested that lowering the f-Hb threshold and extending the screening interval could possibly enhance population-based screening programmes.
In our pilot evaluation of FIT-based screening in Scotland, a much higher f-Hb threshold (≥ 80 µg Hb/g faeces) was employed. 2 Moreover, a much larger cohort of screened individuals (30,893) was available for study. 753 participants with f-Hb ≥ 80 μg Hb/g were referred for colonoscopy. Of 30,140 with a negative screening test result, 27,890 that had participated were eligible to be invited for the next screening round (January 2011 to January 2013). Of 24,669 responders, 450 had a positive screening test result and were referred for colonoscopy. In the two rounds of screening studied, the first with quantitative FIT using a threshold of ≥ 80 µg Hb/g faeces and the second using the standard gFOBT/FIT two-tier reflex algorithm used in Scotland, 3 the positivity in the first round was 2.5%: there were 30 screen-detected cancers (SDC) and 31 interval cancers (IC). 4 In the first round, 753 colonoscopies were performed. At the second round, there were 25 SDC, making a total of 55 SDC over two rounds.
Assuming that IC and CRC detected at the subsequent screening round would have been present in some form during the initial screening round, the scenarios that would have eventuated by omitting the second screening round and using lower f-Hb thresholds are listed in Table 1 
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